Swipe om te navigeren naar een ander artikel
The online version of this article (doi:10.1007/s11136-016-1428-x) contains supplementary material, which is available to authorized users.
Generic preference-based quality of life (PbQoL) measures are sometimes criticized for being insensitive or failing to capture important aspects of quality of life (QoL) in specific populations. The objective of this study was to systematically review and assess the construct validity and responsiveness of PbQoL measures in Parkinson’s.
Ten databases were systematically searched up to July 2015. Studies were included if a PbQoL instrument along with a common Parkinson’s clinical or QoL measure was used, and the utility values were reported. The PbQoL instruments were assessed for construct validity (discriminant and convergent validity) and responsiveness.
Twenty-three of 2758 studies were included, of which the majority evidence was for EQ-5D. Overall good evidence of discriminant validity was demonstrated in the Health Utility Index (HUI)-3, EQ-5D-5L, EQ-5D-3L, 15D, HUI-2, and Disability and Distress Index (DDI). Nevertheless, HUI-2 and EQ-5D-3L were shown to be less sensitive among patients with mild Parkinson’s. Moderate to strong correlations were shown between the PbQoL measures (EQ-5D-3L, EQ-5D-5L, 15D, DDI, and HUI-II) and Parkinson’s-specific measures. Twelve studies provided evidence for the assessment of responsiveness of EQ-5D-3L and one study for 15D, among which six studies reached inconsistent results between EQ-5D-3L and the Parkinson’s-specific measures in measuring the change overtime.
The construct validity of the PbQoL measures was generally good, but there are concerns regarding their responsiveness to change. In Parkinson’s, the inclusion of a Parkinson’s-specific QoL measure or a generic but broader scoped mental and well-being focused measure to incorporate aspects not included in the common PbQoL measures is recommended.
Log in om toegang te krijgen
Met onderstaand(e) abonnement(en) heeft u direct toegang:
Supplementary material 1 (DOCX 24 kb)11136_2016_1428_MOESM1_ESM.docx
National Institute for Health and Care Excellence. Glossary—QALYs. https://www.nice.org.uk/glossary?letter=q. Accessed 09 Apr 2015.
National Institute for Health and Care Excellence. (2012). Appendix G: Methodology checklist: economic evaluations (PMG6B). https://www.nice.org.uk/article/pmg6b/chapter/appendix-g-methodology-checklist-economic-evaluations. Accessed 07 April 2016.
von Neumann, J., & Morgenstern, O. (1944). Theory of games and economic behaviour. Princeton: Princeton University Press.
Holloway, C. (1979). Decision making under uncertainty: models and choices. Englewood Cliffs: Prentice-Hall.
Torrance, G. W., Thomas, W. H., & Sackett, D. L. (1972). A utility maximization model for evaluation of health care programs. Health Service Research, 7(2), 118–133.
EuroQol Group. (1990). EuroQol–a new facility for the measurement of health-related quality of life. Health Policy, 16(3), 199–208. CrossRef
National Institute for Health and Care Excellence. (2013). PMG9 guide to the methods of technology appraisal. 5.3 measuring and valuing health effects. https://www.nice.org.uk/article/pmg9/chapter/the-reference-case#measuring-and-valuing-health-effects. Accessed 07 April 2016.
Garau, M., Shah, K., Towse, A., Wang, Q., Drummond, M., Mason, A. (2009). Assessment and appraisal of oncology medicines: Does NICE’s approach include all relevant elements? What can be learnt from international HTA experiences? Report for the Pharmaceutical Oncology Initiative (POI). Office of Health Economics, London. https://www.ohe.org/publications/assessment-and-appraisal-oncology-medicines-nices-approach-and-international-hta. Accessed 16 Aug 2015.
Wailoo, A., Davis, S., & Tosh, J. (2010). The incorporation of health benefits in cost utility analysis using the EQ-5D. Report by the decision support unit http://www.nicedsu.org.uk/PDFs%20of%20reports/DSU%20EQ5D%20final%20report%20-%20submitted.pdf. Accessed 20 July 2015.
Longworth, L., Yang, Y., Young, T., Mulhern, B., Hernandez Alava, M., Mukuria, C., et al. (2014). Use of generic and condition-specific measures of health-related quality of life in NICE decision-making: a systematic review, statistical modelling and survey. Health Technology Assessment, 18(9), 1–224. CrossRefPubMedPubMedCentral
McDonough, C. M., Grove, M. R., Tosteson, T. D., Lurie, J. D., Hilibrand, A. S., & Tosteson, A. N. (2005). Comparison of EQ-5D, HUI, and SF-36-derived societal health state values among spine patient outcomes research trial (SPORT) participants. Quality of Life Research, 14(5), 1321–1332. CrossRefPubMedPubMedCentral
Macran, S., Weatherly, H., & Kind, P. (2003). Measuring population health: a comparison of three generic health status measures. Medical Care, 41(2), 218–231. PubMed
Richardson, J., Khan, M. A., Iezzi, A., & Maxwell, A. (2015). Comparing and explaining differences in the magnitude, content, and sensitivity of utilities predicted by the EQ-5D, SF-6D, HUI 3, 15D, QWB, and AQoL-8D multiattribute utility instruments. Medical Decision Making, 35(3), 276–291. CrossRefPubMed
Jenkinson, C., Fitzpatrick, R., Peto, V., Harris, R., & Saunders, P. (2008). The Parkinson’s disease questionnaire PDQ-39 user manual (including PDQ-9 and PDQ summary index): Health Services Research Unit (2nd ed.). Oxford: University of Oxford.
Brazier, J. E., Rowen, D., Mavranezouli, I., Tsuchiya, A., Young, T., Yang, Y., et al. (2012). Developing and testing methods for deriving preference-based measures of health from condition-specific measures (and other patient-based measures of outcome). Health Technology Assessment, 16(32), 1–114. CrossRef
Cronbach, L. J., & Meehl, P. E. (1955). Construct validity in psychological tests. Psychological Bulletin—American Psychological Association, 52(4), 281–302.
Bowling, A., & Ebrahim, S. (2005). Handbook of health research methods. Investigation, measurement and analysis. Open University Press, Maidenhead.
Brazier, J., Deverill, M., Green, C., Harper, R., & Booth, A. (1999). A review of the use of health status measures in economic evaluation. Health Technology Assessment, 3(9), 1–164.
Hattie, J., & Cooksey, R. (1984). Procedures for assessing the validities of tests using the “known-groups” method. Applied Psychological Measurement, 8(3), 295–305. CrossRef
Carmines, E. G., & Zeller, R. A. (1979). Reliability and validity assessment. Beverly Hills: Sage. CrossRef
Stratford, P. W., Binkley, J. M., Riddle, D. L., & Guyatt, G. H. (1998). Sensitivity to change of the Roland-Morris back pain questionnaire: Part 1. Physical Therapy, 78(11), 1186–1196. PubMed
Luo, N., Low, S., Lau, P. N., Au, W. L., & Tan, L. C. (2009). Is EQ-5D a valid quality of life instrument in patients with Parkinson’s disease? A study in Singapore. ANNALS Academy of Medicine Singapore, 38(6), 521–528.
Martinez-Martin, P., Rodriguez-Blazquez, C., Forjaz, M. J., Alvarez-Sanchez, M., Arakaki, T., Bergareche-Yarza, A., et al. (2014). Relationship between the MDS-UPDRS domains and the health-related quality of life of Parkinson’s disease patients. European Journal of Neurology, 21(3), 519–524. CrossRefPubMed
Rodriguez-Blazquez, C., Rojo-Abuin, J. M., Alvarez-Sanchez, M., Arakaki, T., Bergareche-Yarza, A., Chade, A., et al. (2013). The MDS-UPDRS Part II (motor experiences of daily living) resulted useful for assessment of disability in Parkinson’s disease. Parkinsonism & Related Disorders, 19(10), 889–893. CrossRef
Daley, D. J., Deane, K. H., Gray, R. J., Clark, A. B., Pfeil, M., Sabanathan, K., et al. (2014). Adherence therapy improves medication adherence and quality of life in people with Parkinson’s disease: a randomised controlled trial. International Journal of Clinical Practice, 68(8), 963–971. CrossRefPubMed
Reuther, M., Spottke, E. A., Klotsche, J., Riedel, O., Peter, H., Berger, K., et al. (2007). Assessing health-related quality of life in patients with Parkinson’s disease in a prospective longitudinal study. Parkinsonism & Related Disorders, 13(2), 108–114. CrossRef
Gudex, C., & Kind, P. (1989). The QALY tool kit—Discussion Paper 38. York: Centre for Health Economics, University of York. http://www.york.ac.uk/che/pdf/dp38.pdf. Accessed 01 April 2016.
Soh, S.-E., Morris, M. E., & McGinley, J. L. (2011). Determinants of health-related quality of life in Parkinson’s disease: A systematic review. Parkinsonism & Related Disorders, 17(1), 1–9. CrossRef
Sung, L., Greenberg, M. L., Doyle, J. J., Young, N. L., Ingber, S., Rubenstein, J., et al. (2003). Construct validation of the health utilities index and the child health questionnaire in children undergoing cancer chemotherapy. British Journal of Cancer, 88(8), 1185–1190. CrossRefPubMedPubMedCentral
Winter, Y., Lubbe, D., Oertel, W. H., & Dodel, R. (2012). Determining minimal clinically important difference for healthrelated quality of life scales in Parkinson’s disease. Movement Disorders, 27, S106. CrossRef
- Assessment of the construct validity and responsiveness of preference-based quality of life measures in people with Parkinson’s: a systematic review
- Springer International Publishing